2000 News Archive
Angiotensin vaccine enters phase II trials following evidence of proof of concept in phase I
30 November 2000
Protherics PLC, a UK-based biotechnology company, is pleased to announce that analysis of results from the Phase I trial of its angiotensin vaccine indicates that the product was able to lower blood pressure in normal volunteers. Supported by these encouraging results, the product will now enter Phase II trials.
Protherics signs virtual screening contracts with Zeneca Agrochemicals and Cytopia
23 October 2000
Protherics PLC has signed contracts to provide virtual screening services to Zeneca Agrochemicals, the crop protection and plant science business of AstraZeneca, and Cytopia, an Australian biopharmaceutical company.
CroFab, Crotalidae polyvalent immune Fab (OVINE), Rattlesnake antivenin receives FDA approval
04 October 2000
Protherics PLC announced today that its rattlesnake antivenin (antivenom), CroFab, developed under the trademark of CroTAb, has been granted approval for marketing by the U.S. Food and Drug Administration (FDA).
Issue of convertible debentures to raise £6.5 million
25 April 2000
Protherics plc ("Protherics" or the "Company") today announces that it has entered into a conditional agreement with funds managed by Citadel Investment Group, L.L.C. and Angelo Gordon & Co. (together the "Investors") to issue convertible unsecured debentures (the "Convertible Debentures") to raise £6.5 million with an option to subscribe for a further £6.5 million.
2007 News
2006 News Archive
2005 News Archive
2004 News Archive
2003 News Archive
2002 News Archive
2001 News Archive
2000 News Archive